Vensica Medical Secures FDA IND Clearance to Launch Phase 2 Trial of ViXe, a Needle-Free Xeomin® Delivery System for Overactive Bladder
Vensica Medical, an emerging innovator in the field of needle-free therapeutic delivery technologies, has announced a significant regulatory milestone with the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration. This approval enables the company to move forward with a Phase 2 clinical trial evaluating its proprietary ViXe program, which combines the Vibe® ultrasound-based delivery platform with Xeomin (incobotulinumtoxinA) for the treatment of overactive bladder (OAB).
This milestone marks an important step forward not only for Vensica but also for the broader field of urologic therapeutics, where there is a growing need for less invasive, patient-friendly treatment options. The ViXe program is specifically designed to address longstanding challenges associated with the administration of botulinum toxin therapies, which, despite their proven effectiveness, are currently limited by the requirement for needle-based delivery.
Overactive bladder is a highly prevalent condition that affects an estimated 33 million adults in the United States alone. It is characterized by symptoms such as urinary urgency, increased frequency, and in many cases, urge incontinence. These symptoms can significantly impact quality of life, leading to social embarrassment, disrupted sleep, and decreased productivity. While first-line treatments typically include behavioral interventions and oral medications, many patients fail to achieve adequate symptom control and require second-line therapies.
One of the most widely used second-line treatments for OAB involves the intravesical injection of botulinum toxin directly into the bladder wall. This approach has been shown to effectively reduce symptoms by relaxing the bladder muscle and decreasing involuntary contractions. However, the procedure is invasive, requiring cystoscopic guidance and multiple needle injections into the bladder lining. As a result, many patients are reluctant to undergo the treatment, and some healthcare providers may be hesitant to recommend it due to the procedural complexity and associated risks.
Vensica’s ViXe program seeks to overcome these limitations by offering a completely needle-free alternative. At the core of this approach is the company’s Vibe® platform, which utilizes proprietary ultrasound technology to facilitate the delivery of large-molecule drugs across biological barriers. By enabling the non-invasive penetration of botulinum toxin into the bladder wall, the Vibe system has the potential to replicate the therapeutic benefits of traditional injections while significantly improving patient comfort and accessibility.
The upcoming Phase 2 clinical trial will be a critical step in validating this innovative approach. The study is expected to enroll approximately 210 patients across multiple clinical sites in both the United States and Europe. Participants will receive treatment using the Vibe-enabled delivery system in combination with botulinum toxin type A, and the trial will assess both safety and efficacy endpoints. These may include reductions in urinary urgency episodes, improvements in bladder capacity, and overall quality-of-life measures.
Patient enrollment for the trial is anticipated to begin in the third quarter of 2026. If successful, the study could provide compelling evidence to support the continued development of the ViXe program and potentially pave the way for larger pivotal trials in the future. Moreover, positive results could position Vensica as a leader in the emerging field of needle-free drug delivery for urologic conditions.
Company leadership has expressed strong confidence in the potential of the ViXe program and the underlying Vibe technology. Avner Geva, Chief Executive Officer of Vensica Medical, emphasized that the FDA’s clearance of the IND application serves as a validation of the scientific and clinical rationale behind the program. He noted that while botulinum toxin is already a well-established therapy for OAB, the reliance on needle-based delivery has limited its adoption. By removing this barrier, Vensica aims to make the treatment accessible to a much broader patient population.
Avi Eftel, Co-Founder and Chief Technology Officer, highlighted the engineering advancements that have made the Vibe platform possible. According to Eftel, one of the primary challenges in drug delivery is overcoming the natural biological barriers that prevent large molecules from penetrating tissues. The Vibe system was specifically designed to address this issue, using ultrasound energy to enhance permeability and facilitate targeted delivery. He expressed optimism about the upcoming trial and the opportunity to generate robust clinical data demonstrating the platform’s effectiveness.
Ken Berlin, Executive Chairman of the Board, also underscored the strategic importance of the IND clearance. He described it as a key inflection point in Vensica’s development journey, noting that a successful needle-free delivery system for botulinum toxin could significantly expand patient access and create substantial value across the healthcare ecosystem. This includes benefits not only for patients but also for healthcare providers, payers, and industry partners.
The IND clearance has also triggered a contractual development milestone payment from Vensica’s strategic partners, providing additional financial support for the execution of the Phase 2 trial. This backing reflects strong confidence from the company’s collaborators, which include Merz Pharma, Laborie, and Israel Biotech Fund. These partnerships not only provide funding but also bring valuable expertise in drug development, commercialization, and market access.
In a broader context, Vensica’s progress highlights the growing interest in innovative drug delivery technologies that can improve patient experience and expand the reach of existing therapies. Needle-free systems, in particular, are gaining attention for their potential to reduce pain, minimize complications, and increase treatment adherence. As healthcare continues to move toward more patient-centric models, solutions like ViXe could play an increasingly important role in shaping the future of care.
In summary, the FDA’s clearance of Vensica Medical’s IND application represents a major milestone for the company and a promising development for patients with overactive bladder. By advancing a novel, needle-free approach to delivering botulinum toxin therapy, Vensica is addressing a critical unmet need and opening the door to more accessible and effective treatment options. The results of the upcoming Phase 2 trial will be closely watched as the company continues its mission to transform the management of urologic diseases through innovative technology.
About Vensica Medical
Vensica Medical is a clinical-stage company developing needle-free therapeutic delivery solutions for urologic diseases. The Company’s proprietary Vibe® platform uses focused ultrasound to enable localized delivery of biologic and small-molecule drugs into the bladder wall. Vensica’s lead program, ViXe, combines the Vibe system with Xeomin® (incobotulinumtoxinA) for the treatment of overactive bladder.
Source Link:https://www.businesswire.com/
